Skip to main content
. 2018 Nov 21;8:532. doi: 10.3389/fonc.2018.00532

Figure 2.

Figure 2

Interactions between radiochemotherapy and PD-1/PD-L1 blockade in the TME. Radiochemotherapy can increase the release of TAAs and DAMPs, improve the expression of PD-L1 on the tumor surface. Some chemotherapeutic agents can also deplete immunosuppressive cells (Tregs and MDSCs), promote the function of APCs, and increase the sensitivity of tumors to cytotoxic immune cells, thereby improving the therapeutic efficacy of PD-1/PD-L1 blockade immunotherapy.